NMRD 0.12 Nemaura Medical Inc.
| Range: | 0.003-0.39 | Vol Avg: | 9164 | Last Div: | 0 | Changes: | 0 |
| Beta: | -0.04 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Feb 05 2018 | Empoloyees: | 36 | ||
| CUSIP: | 640442208 | CIK: | 0001602078 | ISIN: | US6404422080 | Country: | US |
| CEO: | Dr. Dewan Fazlul Hoque Chowdhury Ph.D. | Website: | https://nemauramedical.com | ||||
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow